What You Need to Know About Ofev

What You Need to Know About Ofev

Ofev (nintedanib) is a drug used in the treatment of idiopathic pulmonary fibrosis (IPF). The anti-fibrotic therapy is made by the pharmaceutical company Boehringer Ingelheim and was approved by the FDA in October 2014 and by the European Commission in January 2015. MORE: New knowledge about Ofev and Esbriet may…

Targeting 2 Proteins in Lungs, Including Cannabinoid Receptor, is Potential Therapy for IPF

An investigative therapy for idiopathic pulmonary fibrosis (IPF) based on inhibiting two proteins, including the cannabinoid CB1 receptor, shows potential for halting fibrosis progression, and greatly improved survival in a mouse model for human IPF. The study, “Cannabinoid CB1 receptor overactivity contributes to the pathogenesis of idiopathic pulmonary fibrosis,” was published…

The Travails of Dealing with Supplemental Oxygen

I try to stay positive while also being realistic about the hardships that go with using supplemental oxygen 24/7. But this week I’m irritated and worn-out from the hassles I deal with daily. Here’s me being real. I’m tired of: Having to fight with my insurance and…

International Pulmonary Fibrosis Summit Scheduled for November in Nashville

The Pulmonary Fibrosis Foundation’s 2017 Summit, where pulmonary fibrosis researchers and community members from around the world can share information and experiences, will be Nov. 9-11 in Nashville, the foundation announced. Summit organizers encourage researchers, physicians, academics, industry leaders, patients and caregivers to take part in the sessions, which will highlight developments…

Busting Popular Myths About Depression

This video from Big Think deals with some of the common myths surrounding depression. MORE: Did you know that pulmonary fibrosis can be difficult to diagnose and treat?  Dr. Patricia Deldin from the University of Michigan Depression Center explains exactly what depression is and what it isn’t. Deldin shares that…